Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial
|
|
- Stanley Woods
- 5 years ago
- Views:
Transcription
1 Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial Amit G. Singal MD MS UT Southwestern Medical Center and Parkland Health & Hospital System Dallas, TX, USA 1
2 Hepatocellular carcinoma is a global problem Age-adjusted incidence rates per 100,000 person-years 2
3 Incidence of HCC is rapidly increasing Black race White race 3 Created by statecancerprofiles.cancer.gov on December 8, 2013
4 Mortality rate of HCC is rapidly increasing Created by statecancerprofiles.cancer.gov on December 8,
5 Curative options exist for early stage HCC 5 Bruix et al Hepatology 2010
6 HCC screening is recommended 6
7 HCC screening reduces mortality in chronic hepatitis B Screening Control Stage I 60.5% 0% Stage II 13.9% 37.3% Stage III 25.6% 62.7% Curative treatment 2-year survival 46.5% 7.5% 59.9% 7.2% 7 Zhang et al Cancer Res Oncol 2004
8 HCC screening associated with early stage detection in patients with cirrhosis 8 Singal et al PLOS Medicine 2014
9 HCC Screening is underutilized 9 Singal et al, J Gen Intern Med 2012
10 There are racial and socioeconomic disparities in HCC screening receipt Screening rates assessed in 904 patients Inconsistent surveillance: 66.7% Consistent annual surveillance: 13.4% Consistent biannual surveillance: 1.7% Predictors of Screening Multivariate analysis Insurance status OR 1.43, 95%CI African American race OR 0.61, 95%CI Extrahepatic cancer OR 0.43, 95%CI Multiple primary care visits OR 2.63, 95%CI Hepatology care OR 3.75, 95%CI Singal et al Am J Medicine 2015
11 Why is screening not being utilized? 11 Singal et al, Cancer Prevent Research 2012
12 Primary care providers report multiple barriers to HCC screening Provider-reported barriers Percent Lack of knowledge about guidelines 68.2% Competing interests in clinic 51.6% Lack of time in clinic 40.5% Difficulty recognizing at-risk patients 35.4% Ultrasound capacity 23.0% Doubt patients will complete 9.3% 12 Dalton-Fitzgerald et al Clin Gastro Hep (in press)
13 Patients are knowledge and accepting of HCC screening Patient knowledge and attitudes Percent (n=541) HCC surveillance is important to perform 88.8% Knowledge about surveillance is important 89.5% Patients with cirrhosis are high risk for HCC 90.8% Ultrasound should be done every 6-12 mo 88.4% Lack of trust in ultrasound quality 13.9% Fear of pain related to ultrasound 9.5% Fear of finding cancer 11.3% Costs of screening tests 25.3% 13 Farvardin et al (submitted)
14 Population-based management can increase surveillance rates Study # Pts Intervention Effect size Aberra Quasi study of nurse-based protocol 74% vs. 93% Wigg RCT of automated reminders 89% vs. 100% Beste Quasi study of point-of-care reminders 18% vs. 28% 14
15 Specific Aims Compare the clinical effectiveness and patient acceptability of intervention strategies to increase one-time HCC screening rates Evaluate whether intervention effects are moderated by patient characteristics including sex, race, ethnicity, and English proficiency 15
16 Study Setting Randomized trial comparing 3 strategies for HCC surveillance Arm 1: Usual visit-based surveillance by clinic providers Arm 2: Mailed surveillance outreach Arm 3: Mailed surveillance outreach + patient navigation Setting: Parkland Health & Hospital System Publicly funded integrated health system that serves as sole safety-net institution for Dallas County, TX Medical assistance plan for underinsured and uninsured patients 16
17 Inclusion and Exclusion Criteria Inclusion: Patients with documented or suspected cirrhosis Documented cirrhosis was defined using ICD-9 codes for cirrhosis or cirrhosis-related complications Suspected cirrhosis defined as AST to platelet ratio index (APRI) 1.5 in the presence of liver disease Exclusion: Patients with Child C cirrhosis who were not transplant candidates and those with significant comorbid conditions given limited benefit of HCC surveillance 17
18 Outreach Intervention Patients in Arms 2 and 3 received one-page letter Basic information about HCC risk Invitation with phone number to schedule ultrasound for HCC surveillance Low-literacy letters in English and Spanish Telephone reminder calls for patients who did not respond within 2 weeks Patients in Arm 3 also received reminder telephone calls one week prior to ultrasound Staff could help reschedule exams as needed 18
19 Copy of Patient Letter 19
20 Patient Stakeholder engagement Patient experiences prompted research I don t get it. I ve been seeing my doctors for years and do everything he says. How come they didn t find it earlier? Feedback from patients Liked idea of Parkland reaching out to them and reminding them vs. waiting to be seen in clinic Found invitation letter helpful and telephone call script clear but provided specific input for minor changes 20
21 Patient Stakeholder engagement Patient Advocacy Groups Reviewed invitation letter and phone scripts Interested in help with dissemination of results Providers Primary care providers, Liver Tumor Clinic providers, and radiologists re: study logistics of ordering/scheduling exams and follow-up System administration Discussed increased healthcare utilization and costs but benefit to Parkland patients 21
22 Statistical Analysis Primary outcome was one-time screening completion Abdominal imaging within 6 months of randomization Pearson chi-square analysis to compare across 3 arms Secondary outcomes Time-to-response to outreach invitations: early responders vs. late responders vs. non-responders Proportion of HCC detected at an early stage Pearson chi-square analysis to compare both secondary outcomes across 3 arms 22
23 Study Consort Diagram 23
24 Patient Characteristics Overall (N=1800) Arm 1 (n=600) Arm 2 (n=600) Arm 3 (n=600) Age (years) 55 (21-87) 54 (22-83) 55 (24-87) 55 (28-85) Sex (% male) 1069 (59.4%) 350 (58.3%) 361 (60.2%) 358 (59.7%) Race/ethnicity White Black Hispanic Other 510 (28.3%) 578 (32.1%) 681 (37.8%) 31 (1.7%) 182 (30.3%) 186 (31.0%) 217 (36.2%) 15 (2.5%) 165(27.5%) 197 (32.8%) 230 (38.3%) 8 (1.3%) 163 (27.2%) 195 (32.5%) 234 (39.0%) 8 (1.3%) Cirrhosis etiology HCV Alcohol-related NASH HBV 918 (51.0%) 317 (17.6%) 299 (16.6%) 62 (3.4%) 320 (53.3%) 98 (16.3%) 104 (17.3%) 21 (3.5%) 285 (47.5%) 115 (19.2%) 101 (16.8%) 27 (4.5%) 313 (52.2%) 104 (17.3%) 94 (15.7%) 14 (2.3%) Child Pugh A 1291 (71.7%) 432 (72.0%) 435 (72.5%) 424 (70.7%) 24
25 One-time HCC Screening Rates Imaging-based HCC screening rates were significantly higher in the outreach alone (Arm 2) and outreach/patient navigation (Arm 3) arms than usual care (Arm 1) (p<0.001 for both comparisons) Imaging-based HCC screening rates did not significantly differ between the two outreach arms 25
26 One-time HCC Screening Rates No difference in intervention effect by gender, race, or known cirrhosis status 26
27 Subgroup Analyses: Arm 1 vs. 2 27
28 Subgroup Analyses: Arm 2 vs. 3 28
29 Predictors of Screening Receipt Variable Univariate analysis Multivariate analysis* Outreach Strategy Usual Care Outreach Alone Outreach + Navigation Age (years) Ref ( ) 3.34 ( ) Ref ( ) 3.47 ( ) Ref ( ) 1.39 ( ) Ref ( ) 1.15 ( ) Male gender 0.77 ( ) 0.80 ( ) Race/ethnicity Caucasian Hispanic Black Reference 1.52 ( ) 1.21 ( ) Reference 1.56 ( ) 1.14 ( ) Suspected cirrhosis 1.70 ( ) 0.82 ( ) Number primary care visits 1.07 ( ) 1.05 ( ) Receipt of hepatology care 2.01 ( ) 1.74 ( ) * Also adjusted for Charlson comorbidity index and Child Pugh class 29
30 Early vs. Late Responders Early Responders Late Responders Non Responders Any outreach (n=1200) 161(13.4%) 424 (35.3%) 615 (51.3%) Arm 2 (n=600) 78 (13.0%) 210 (35.0%) 312 (52.0%) Arm 3 (n=600) 83 (13.8%) 214 (35.7%) 303 (50.5%) Early responder median time to response was 8 days Late responder median time to response was 32 days 30
31 Hepatocellular carcinoma outcomes Usual care (n=9) Any outreach (n=10) Screening US Missed by US Incidental CT/MRI Detected between 6-12 months 1 (11.1%) 1 (11.1%) 2 (22.2%) 5 (55.5%) 1 (10.0%) 1 (10.0%) 5 (50.0%) 3 (30.0%) 66.7% (n=6) usual care patients found at early stage 80.0% (n=8) intervention patients found at early stage 31
32 Summary Outreach strategies can significantly increase onetime HCC screening rates among patients with cirrhosis Adding patient navigation to telephone screening reminders provided no significant additional benefit. Our ongoing study is evaluating the effectiveness of outreach strategies for increasing repeat HCC surveillance rates and downstream outcomes, including early tumor detection 32
33 Next Steps Expansion to assess if can be generalized to other health systems CPRIT multi-investigator grant at 3 sites (safety-net, academic system, and VA) Effectiveness for screening process completion Repeat testing over one-year period, follow-up for abnormal screening results, and evaluation if diagnosed with HCC Qualitative interviews among non-responders Screening participation rates still <50% so can inform future interventions 33
34 Acknowledgements Katharine McCallister Joanne Sanders Caroline Mejias Jasmin Tiro Ethan Halm Jorge Marrero Conducted as part of the Center for Patient-Centered Outcomes Research with support from AHRQ Grant R24 HS
SCREEN, TREAT, OR PREVENT HCC:
SCREEN, TREAT, OR PREVENT HCC: Liver Cancer Prevention in Texas Baby Boomers Barbara J Turner MD, MSEd Founding Director, Center for Research to Advance Community Health University of Texas Health San
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationDetection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
nature publishing group ORIGINAL CONTRIBUTIONS 1 see related editorial on page x Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationSandra Tilmon, MPH Research Manager The University of Chicago Clinical Directors Network, (CDN) Webcast November 9 th, 2018
{ Sandra Tilmon, MPH Research Manager The University of Chicago Clinical Directors Network, (CDN) Webcast November 9 th, 2018 ACKNOWLEDGEMENT This presentation was funded through a Patient-Centered Outcomes
More informationGender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,
Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project, 2009-2010 Linda Beer PhD, Christine L Mattson PhD, William Rodney Short MD,
More informationPredictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis
Alimentary Pharmacology and Therapeutics Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis O. Simmons*, D. T. Fetzer, T. Yokoo,J.A.Marrero*,A.Yopp,
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationPositive Results on Fecal Blood Tests
Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests Results of a systematic review and Kaiser experience Kevin Selby, M.D. kevin.j.selby@kp.org National Colorectal Cancer Roundtable
More informationPrimary liver cancer is the second-leading cause of
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 65, NO. 4, 2017 HEPATOBILIARY MALIGNANCIES An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationKaren E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago
Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago 1 2 billion people have been exposed to HBV 350-400 million people chronically
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationTransforming Hepatitis B Care in Kaiser Permanente Mid-Atlantic States Through a Registry and Coordinator Supported Pathway
Transforming Hepatitis B Care in Kaiser Permanente Mid-Atlantic States Through a Registry and Coordinator Supported Pathway V3.28.19c Michael Horberg, MD, MAS, FACP, FIDSA Executive Director Research,
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHEPATOCELLULAR CARCINOMA: AN OVERVIEW
HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF
More informationPresentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1284 1290 Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection
More informationIMPACT OF AREA-POVERTY RATE ON LATE-STAGE COLORECTAL CANCER INCIDENCE IN INDIANA, NAACCR JUNE 22, 2017
IMPACT OF AREA-POVERTY RATE ON LATE-STAGE COLORECTAL CANCER INCIDENCE IN INDIANA, 2010-2014 NAACCR JUNE 22, 2017 Aaron Cocke, Amanda K. Raftery, Timothy McFarlane SECTION 1 OVERVIEW OF PROJECT Purposes
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationInterventions to Improve Follow-up of Positive Results on Fecal Blood Tests
Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests Results of a systematic review, Kaiser experience, and implications for the Canton of Vaud Kevin Selby, M.D. Kevin.Selby@hospvd.ch
More informationEarly Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis
Early Detection, Curative, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis Amit G. Singal 1,2,3 *, Anjana Pillai 4, Jasmin Tiro 2,3 1 Department
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationDuring the past 2 decades, an increase in the ageadjusted
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:104 110 Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study JESSICA A. DAVILA* and HASHEM B. EL SERAG*,
More informationTHE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationACHIEVING HEALTH EQUITY IN LAKE COUNTY HOW DO WE GET THERE?
ACHIEVING HEALTH EQUITY IN LAKE COUNTY HOW DO WE GET THERE? Achieving Health Equity in Lake County How Do we get there? Photo: Flickr user JanetandPhil / Creative Commons (BY-NC-ND 2.0) 2 Achieving Health
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationElectra D. Paskett, Ph.D. The Ohio State University Multi-level Approaches to Addressing Cancer Disparities
Electra D. Paskett, Ph.D. The Ohio State University Multi-level Approaches to Addressing Cancer Disparities February 3-5, 2016 Lansdowne Resort, Leesburg, VA Models to Understand and Address Disparities
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationBreast and Cervical Cancer Early Detection BEST PRACTICES AND MODELS
Breast and Cervical Cancer Early Detection BEST PRACTICES AND MODELS PRESENTED BY: LATHANHARRIS, INC. PRESENTATION OBJECTIVES Describe disparity issues for African American women Describe barriers African
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care
More informationDisparities in Vison Loss and Eye Health
Disparities in Vison Loss and Eye Health Xinzhi Zhang, MD, PhD, FACE, FRSM National Institute on Minority Health and Health Disparities National Institutes of Health Disclaimer The findings and conclusions
More informationUsing Patient Navigation to Impact Trust in the Health Care System
Using Patient Navigation to Impact Trust in the Health Care System ARANTZA RODRIGUEZ PUERTOS MENTOR: CARMEN E. GUERRA, M.D., M.S.C.E., F.A.C.P. Introduction Data and Methods Outline Key Findings and Discussion
More informationHealth Disparities Research. Kyu Rhee, MD, MPP, FAAP, FACP Chief Public Health Officer Health Resources and Services Administration
Health Disparities Research Kyu Rhee, MD, MPP, FAAP, FACP Chief Public Health Officer Health Resources and Services Administration Outline on Health Disparities Research What is a health disparity? (DETECT)
More informationCamden Citywide Diabetes Collaborative
Camden Citywide Diabetes Collaborative The Camden Coalition of Healthcare Providers is an organization that seeks to improve the quality, capacity and accessibility of the health care system for vulnerable,
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationC A LIFORNIA HEALTHCARE FOUNDATION. Drilling Down: Access, Affordability, and Consumer Perceptions in Adult Dental Health
C A LIFORNIA HEALTHCARE FOUNDATION s n a p s h o t Drilling Down: Access, Affordability, and Consumer Perceptions in 2008 Introduction Although many Californians have dental insurance, even those with
More informationRETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC
SATELLITE SYMPOSIUM Emerging Horizons in HCC: From Palliation to Cure RETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC Professor Riccardo Lencioni, MD, FSIR, EBIR University of Pisa School of Medicine,
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationUnderstanding your epidemic: WHO tools for hepatitis surveillance
. Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationLeveraging Social Networks to Promote Cancer Prevention Health Behaviors
Leveraging Social Networks to Promote Cancer Prevention Health Behaviors Dr. Jaya Aysola MD, MPH Jazmine Smith Masters in Criminology Candidate, Sarah Griggs MPH, Sitara Soundar MD candidate, Gabrielle
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationInverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma
DOI:10.1111/j.1477-2574.2012.00507.x HPB ORIGINAL ARTICLE Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma Umut Sarpel 1, Diego Ayo 2, Iryna Lobach 3, Ruliang Xu 4
More informationDeveloping Systems to Increase Colorectal Cancer Screening at Health Centers
Northwestern University Feinberg School of Medicine Developing Systems to Increase Colorectal Cancer Screening at Health Centers David R. Buchanan, MD, MS Chief Clinical Officer, Erie Family Health Center
More informationHEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017
HEPATITIS C Whitney Dickson, PharmD, BCPS October 12 th, 2017 MY BACKGROUND Pharmacy School: University of California San Diego Pharmacy Practice Residency (PGY1): University of Illinois at Chicago HIV/Hep
More informationNorth Dakota Statewide Cancer Plan Evaluation
North Dakota Statewide Cancer Plan Evaluation Strategy Implementation Does your organization choose strategies to implement because they are suggested in the ND Cancer Control Plan? 72 28 Does your organization
More informationHealth Disparities Research
Health Disparities Research Kyu Rhee, MD, MPP, FAAP, FACP Chief Public Health Officer Health Resources and Services Administration Outline on Health Disparities Research What is a health disparity? (DETECT)
More informationHepatitis C (HCV) Digestive Health Recognition Program
PQRS #84 Hepatitis C: Ribonucleic Acid (RNA) Effective Clinical Process NQF 0395 Testing Before Initiating Treatment Care Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationRacial and Socioeconomic Disparities in Appendicitis
Racial and Socioeconomic Disparities in Appendicitis Steven L. Lee, MD Chief of Pediatric Surgery, Harbor-UCLA Associate Clinical Professor of Surgery and Pediatrics David Geffen School of Medicine at
More informationTABLE 1. Percentage of respondents to a national survey of young adults, by selected characteristics, according to gender, United States, 2009
TABLE 1. Percentage of respondents to a national survey of young adults, by selected characteristics, according to gender, United States, 2009 Characteristic All Females Males (N=1,699) (N=779) (N=920)
More informationCommunity Health Improvement Plan
Community Health Improvement Plan Methodist University Hospital Methodist Le Bonheur Healthcare (MLH) is an integrated, not-for-profit healthcare delivery system based in Memphis, Tennessee, with 1,650
More informationPCORI RESEARCH PLAN Applicants are encouraged to refer to the contents of the PCORI Methodology Report in developing their Research Plan.
PCORI RESEARCH PLAN Applicants are encouraged to refer to the contents of the PCORI Methodology Report in developing their Research Plan. RESEARCH STRATEGY (Use continuation pages as needed to provide
More informationHCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study
Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:989 994 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Level of -Fetoprotein Predicts Mortality Among Patients With Hepatitis C Related Hepatocellular
More informationRacial and Ethnic Disparities in Health and Health Care: The Impact on Women s Health
Racial and Ethnic Disparities in Health and Health Care: The Impact on Women s Health Joseph R. Betancourt, M.D., M.P.H. Director, The Disparities Solutions Center Senior Scientist, Mongan Institute for
More informationHCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification, and Efficacy Research
SIIM 2017 Scientific Session Quality & Performance Improvement Part 2 Friday, June 2 7:00 am 8:00 am HCC Screening Compliance Module: A Tool for Automated Compliance Monitoring, Clinician Notification,
More information2012 AAHPM & HPNA Annual Assembly
Disclosure Patient Navigation Interventions To Improve Palliative Care For The Underserved: Integrating The Voice Of The Community And Scientific Rigor Drs. Fischer and Hauser have no relevant financial
More informationAppendix Annotated Synthesis Matrix
TABLE: HEPATITIS B VIRUS AMONG SOUTHEAST ASIANS 1 Author(s): Damian Roman, Christie Holtzclaw Appendix Annotated Synthesis Matrix Research Question(s): To what extent are Southeast Asian immigrant s in
More informationTaussig Cancer Institute Community Outreach Efforts. Kimberly Kreller RN, BSN Director Community Outreach and Research
Taussig Cancer Institute Community Outreach Efforts Kimberly Kreller RN, BSN Director Community Outreach and Research Team Members Dr. Marc Shapiro, Medical Director Angela Bailey Stacey Booker, RN MSN
More informationIncreasing Cancer Screening: One-on-One Education Breast Cancer
Increasing Cancer Screening: One-on-One Education Breast Cancer Summary Evidence Table Studies from the Updated Search Abood et al. (2005) NR Other design w comparison group Mammography; Record review
More informationScreening and Linkage to Services for Autism (SaLSA):
Screening and Linkage to Services for Autism (SaLSA): Study of Patient Navigation for Low Income Families with Young Children CAROLYN DIGUISEPPI, MD, MPH, PHD COLORADO SCHOOL OF PUBLIC HEALTH Session Objectives
More informationTrends in Seasonal Influenza Vaccination Disparities between US non- Hispanic whites and Hispanics,
Trends in Seasonal Influenza Vaccination Disparities between US non- Hispanic whites and Hispanics, 2000-2009 Authors by order of contribution: Andrew E. Burger Eric N. Reither Correspondence: Andrew E.
More informationHealthcare Disparities and Need for Transplant in our Multicultural Communities
Healthcare Disparities and Need for Transplant in our Multicultural Communities AMAT 20 th Annual Meeting September 19, 2012 Anil S. Paramesh, MD, FACS Associate Professor of Surgery and Urology Tulane
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationWelcome to Progress in Community Health Partnerships latest episode our Beyond the Manuscript podcast. In each
Beyond the Manuscript 91 Podcast Interview Transcript Erin Kobetz, Joan Bloom, Irma Robbins, Kim Engelman Welcome to Progress in Community Health Partnerships latest episode our Beyond the Manuscript podcast.
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationHispanics/Latinos and Hepatitis: An Overlooked Health Disparity. National Hispanic Hepatitis Awareness Day
Hispanics/Latinos and Hepatitis: An Overlooked Health Disparity National Hispanic Hepatitis Awareness Day HELLO! LUIS A. MARES, LMSW Director of Community Mobilization Latino Commission on AIDS. Lmares@latinoaids.org
More informationThe Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes
The Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes SHERYL RILEY RN, OCN, CMCN DIRECTOR OF CLINICAL SERVICES SAI SYSTEMS SRILEY@SAISYSTEMS.COM 2015 SAI SYSTEMS INTERNATIONAL
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More information6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
More informationUnequal Treatment: Disparities in Access, Quality, and Care
Unequal Treatment: Disparities in Access, Quality, and Care Brian D. Smedley, Ph.D. National Collaborative for Health Equity www.nationalcollaborative.org Healthcare Disparities: Are We Making Progress?
More informationFactors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis
Published online: December 17, 2016 Original Paper Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Hager A. Ahmed Mohammed a Ju Dong Yang a Nasra H. Giama
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationProject SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018
Project SUCCEED Scaling up Co Infection Care & Eliminating Ethnic Disparities 13 th Annual Iris House Women As the Face of AIDS Summit May 7th, 2018 2 Project SUCCEED Team Natalie Octave, MPH, CHES Project
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationBuilding Systems to Evaluate Food Insecurity Screening and Diabetes Within an FQHC
Building Systems to Evaluate Food Insecurity Screening and Diabetes Within an FQHC Danielle Lazar, Director of Research, Access Community Health Network Kathleen Gregory, Principal, Kathleen Gregory Consulting,
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationDUPLICATION DISTRIBUTION PROHIBBITED AND. Utilizing Economic and Clinical Outcomes to Eliminate Health Disparities and Improve Health Equity
General Session IV Utilizing Economic and Clinical Outcomes to Eliminate Health Disparities and Improve Health Equity Accreditation UAN 0024-0000-12-012-L04-P Participation in this activity earns 2.0 contact
More informationCervical Cancer Screening and Prevention in Latinas. Sandra Torrente, MD, MSc Kenneth Grullon, MD
ç Cervical Cancer Screening and Prevention in Latinas Sandra Torrente, MD, MSc Kenneth Grullon, MD Objectives Cervical cancer epidemiology Cervical cancer screening rates locally Health Disparities of
More informationTITLE: Quality of Breast Cancer Care: The Role of Hispanic Ethnicity, Language, and Socioeconomic Position
AD Award Number: DAMD17-03-1-0328 TITLE: Quality of Breast Cancer Care: The Role of Hispanic Ethnicity, Language, and Socioeconomic Position PRINCIPAL INVESTIGATOR: Diana M. Tisnado, Ph.D. Katherine L.
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationImplementing and Evaluating a Peer Enhanced Intervention:
Implementing and Evaluating a Peer Enhanced Intervention: Results from a randomized control trial Jane Fox, MPH, Boston University School of Public Health Janet Goldberg, MPH, PATH Center, The Brooklyn
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDiversity in Donation and Transplantation: Lessons from Cancer Care
Diversity in Donation and Transplantation: Lessons from Cancer Care September 23, 2015, AMAT Annual Conference Rishindra M. Reddy, MD, FACS Assistant Professor, Thoracic Surgery University of Michigan
More information